A major gap in our knowledge of rapid hepatic HDL cholesterol clearance is the role of key intracellular factors that influence this process. Although the reverse cholesterol transport pathway targets HDL to the liver for net elimination of free cholesterol from the body, molecular details governing cholesterol uptake into hepatocytes are not completely understood. Therefore, the effects of sterol carrier protein (SCP)-2 and liver fatty acid-binding protein (L-FABP), high-affinity cholesterol-binding proteins present in hepatocyte cytosol, on HDLmediated free cholesterol uptake were examined using gene-targeted mouse models, cultured primary hepatocytes, and 22-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-amino]-23,24-bisnor-5-cholen-3␤-ol (NBD-cholesterol). While SCP-2 overexpression enhanced NBD-cholesterol uptake, counterintuitively, SCP-2/SCP-x gene ablation also 1) enhanced the rapid molecular phase of free sterol uptake detectable in Ͻ1 min and initial rate and maximal uptake of HDL free cholesterol and 2) differentially enhanced free cholesterol uptake mediated by the HDL3, rather than the HDL2, subfraction. The increased HDL free cholesterol uptake was not due to increased expression or distribution of the HDL receptor [scavenger receptor B1 (SRB1)], proteins regulating SRB1 [postsynaptic density protein (PSD-95)/Drosophila disk large tumor suppressor (dlg)/tight junction protein (ZO1) and 17-kDa membrane-associated protein], or other intracellular cholesterol trafficking proteins (steroidogenic acute response protein D, Niemann Pick C, and oxysterol-binding protein-related proteins). However, expression of L-FABP, the single most prevalent hepatic cytosolic protein that binds cholesterol, was upregulated twofold in SCP-2/ SCP-x null hepatocytes. Double-immunogold electron microscopy detected L-FABP sufficiently close to SRB1 for direct interaction, similar to SCP-2. These data suggest a role for L-FABP in HDL cholesterol uptake, a finding confirmed with SCP-2/SCP-x/L-FABP null mice and hepatocytes. Taken together, these results suggest that L-FABP, particularly in the absence of SCP-2, plays a significant role in HDL-mediated cholesterol uptake in cultured primary hepatocytes.
A MAJOR GAP IN OUR KNOWLEDGE of rapid hepatic HDL cholesterol clearance is the role of intracellular factors that influence rapid HDL cholesterol uptake. Low levels and reduced function of HDL correlates with increased risk of cardiovascular disease, but singularly increasing HDL may not stimulate reverse cholesterol transport (RCT) from peripheral cells to liver for clearance into bile (19) . HDL composition and other as yet unresolved intrahepatic factors contribute (19) . Finding these intracellular factors would fill a major gap in our knowledge of RCT and identify new therapeutic targets. Our studies show that hepatocyte cytosol contains high levels of two cholesterolbinding proteins: sterol carrier protein (SCP)-2 and liver fatty acid-binding protein (L-FABP) (3, 33, 52) .
A variety of in vitro studies suggest that SCP-2 and L-FABP are candidate proteins for facilitating rapid uptake of HDL cholesterol by hepatocytes. SCP-2 and L-FABP bind cholesterol with high affinity (22, 33, 35) . SCP-2 and L-FABP enhance cholesterol transfer from purified plasma membranes to intracellular sites in vitro and in transfected cells (25, 41, 48) . SCP-2 directly interacts with the HDL receptor scavenger receptor B1 (SRB1) and in vitro selectively stimulates vectorial sterol transfer from purified hepatocyte plasma membrane cholesterol-rich microdomains (5, 52) . Overexpression of SCP-2 in a liver-derived cell line (McA-RH7777 hepatoma) increased plasma membrane cholesterol internalization and decreased cholesterol secretion to HDL (9) . However, hepatoma cells express much reduced levels of L-FABP compared with liver hepatocytes (28, 58) and do not express the high-K m glucose transporter GLUT2 and glucokinase found in Ͼ98% of liver hepatocytes (54) . Thus the contributions of SCP-2 and L-FABP in primary hepatocytes and mice remain to be resolved.
Importantly, human genetic variations and sexual dimorphism in SCP-2 and L-FABP are associated with significant changes in HDL cholesterol and lipid metabolism. SCP-2 genetic variations inhibit cholesterol metabolism (16) , a phenotype shared by SCP-2 null mice (21) . With human L-FABP, a T94A polymorphism occurs with a frequency of 32-37% (10 -13% homozygous) in Caucasians (18, 46, 57) . This L-FABP T94A substitution results not only in decreased fatty acid uptake and hepatic triglycerides, but also in hepatic cholesterol accumulation (23) and elevated serum LDL cholesterol and triglycerides, traits associated with increased risk of cardiovascular disease and type 2 diabetes (11, 18) . L-FABP T94A overexpression in Chang hepatoma cells, which contain no native L-FABP, exhibited cholesterol accumulation compared with Chang hepatoma cells overexpressing the normal L-FABP T94T (23) .
To begin to resolve the individual contributions of SCP-2 and L-FABP in HDL free cholesterol uptake, we studied SCP-2-overexpressing and gene-ablated (SCP-2/SCP-x null and SCP-2/SCP-x/L-FABP null) mice. Studies in vivo and real-time confocal imaging of the fluorescent cholesterol analog 22-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-amino]-23,24-bisnor-5-cholen-3␤-ol (NBD-cholesterol) were used to examine effects of SCP-2 and L-FABP expression on 1) HDL-mediated unesterified cholesterol uptake and 2) differential uptake of HDL2-vs. HDL3-derived unesterified cholesterol. NBDcholesterol was chosen as a cholesterol analog, since previous studies indicate that NBD-cholesterol was a suitable, nonesterifiable probe for real-time imaging of HDL-mediated uptake via the SRB1 pathway in nonhepatocytes (7, 20) .
MATERIALS AND METHODS

Materials.
Silica gel G TLC plates were obtained from Analtech (Newark, DE). Lipid standards were obtained from Nu-Chek Prep (Elysian, MN). Rabbit polyclonal antisera to recombinant human SCP-2 and L-FABP were prepared as described previously (6) . Goat polyclonal antisera raised against 17-kDa membrane-associated protein (MAP-17), postsynaptic density protein (PSD-95)/Drosophila disk large tumor suppressor (dlg)/tight junction protein (ZO1) (PDZK-1), Niemann Pick C1 (NPC1), Niemann Pick C 2 (NPC2), NPC1-like protein 1 (NPC1L1), metastatic lymph node protein 64 (MLN64)/ steroidogenic acute response protein (StAR) D3, phosphatidylcholine transfer protein (PC-TP)/StARD2, L-FABP, and StAR, as well as rabbit antisera against ATP-binding cassette (ABC) G1, ABCG5, and ABCG8, were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Goat polyclonal antisera against oxysterolbinding protein (OSBP), OSBP-related protein (ORP) 1, ORP2, ORP3, ORP4, ORP5, ORP6, ORP7, ORP9, ORP10, and ORP11, rabbit antisera against ABCA1 and SRB1, and goat SRB1 antibody (NB400-131) were purchased from Novus Biologicals (Littleton, CO). Rabbit polyclonal antisera against StARD4 and StARD5 were obtained from J. Breslow (Rockefeller University). Caveolin-1-directed rabbit antiserum was purchased from BD Biosciences (San Jose, CA). NBD-cholesterol, 6-[(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-hexanoyl] sphingosine (NBD-C6-ceramide) fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit IgG, tetramethylrhodamine isothiocyanate (TRITC)-conjugated goat anti-rabbit IgG, Alexa Fluor 488-conjugated donkey anti-goat IgG, and Alexa Fluor 598-conjugated ␤-subunit of Vibrio cholerae toxin (CT-B) were purchased from Molecular Probes (Eugene, OR). LR White resin, as well as donkey anti-rabbit IgG conjugated to 6-nm gold and donkey anti-goat IgG conjugated to 15-nm gold, were obtained from Electron Microscopy Sciences (Hatfield, PA). Alkaline phosphatase-conjugated rabbit anti-goat IgG and goat anti-rabbit IgG, Dextralip 50, cesium carbonate, and cadmium carbonate were purchased from Sigma-Aldrich (St. Louis, MO). Purified human HDL, LDL, and VLDL were obtained from EMD Biosciences (San Diego, CA). All reagents and solvents were of the highest grade available and were cell culture-tested as necessary.
Animals. All animal protocols were approved by the Institutional Animal Care and Use Committee at Texas A & M University. Wild-type (WT) male C57BL/6NCr mice (8 -10 wk old, 20 -25 g) were purchased from the National Cancer Institute (Frederick Cancer Research and Developmental Center, Frederick, MD). SCP-2/SCP-x null mice were generated by this laboratory (5) and backcrossed to C57BL/6NCr mice to Ն10 generations. L-FABP Ϫ/Ϫ SCP-2/SCP-X Ϫ/Ϫ triple-null (tripleknockout) mice on the C57BL/6NCr background (52) and SCP-2-overexpressing mice and controls (4) are described elsewhere. All mice were kept under a 12:12-h light-dark cycle in a temperature-controlled facility (25°C) with ad libitum access to food (standard rodent chow mix, 5% of calories from fat) and water. Mice were free of all known rodent pathogens, as monitored quarterly.
Hepatocyte isolation and culture. Cultured primary hepatocytes derived from the livers of 10-to 12-wk-old male WT, overexpression, or gene-targeted mice were isolated and cultured as described elsewhere (5). Hepatocytes were cultured for 1, 2, 3, or 4 days, and hepatocyte lysates were subjected to Western blotting to determine expression of SCP-2, L-FABP, SRB1, ABCA1, ABCG1, ABCG5, ABCG8, and NPC1L1. Since expression levels of these proteins were constant for 2-3 days in culture (Fig. 1) , all experiments used hepatocytes at 1-2 days postisolation to ensure that interactions with HDL reflected physiological conditions.
Isolation of lipoproteins, incorporation of NBD-cholesterol, and characterization. HDL2 and HDL3 were isolated from human serum by centrifugation in a self-forming Cs 2Cd-EDTA (0.3 M) gradient, and the density profile was determined by measurement of the refractive indexes of sequential fractions after the centrifugation (27) . Serum HDL2 and HDL3 profiles were determined by labeling with NBD-C6-ceramide and measuring the fluorescence intensities of sequential fractions after centrifugation. The fractions containing HDL2 (density ϭ 1.063-1.1099) and HDL3 (density ϭ 1.1099 -1.179) were pooled on the basis of the predetermined density profiles. NBDcholesterol was incorporated into HDL, HDL2, HDL3, LDL, and VLDL basically as previously described (42) . The protein was quantitated by Bradford assay, and the NBD-cholesterol content was calculated for each fraction (NBD-cholesterol extinction coefficient in methanol ϭ 21,000 cm Ϫ1 ·M Ϫ1 ). Presence of NBD-cholesterol was determined with a fluorescence spectrophotometer (Cary Eclipse, Varian, Palo Alto, CA) using an excitation scan window of 350 -600 nm, 5-nm excitation and emission slit widths, and a 535-nm emission wavelength (maximal emission). Steady-state fluorescence polarization studies were performed to measure NBD-cholesterol fluidity or motional freedom within the HDL samples. Anisotropies of the labeled lipoproteins (5 g protein/ml in 10 nM PIPES buffer, pH 7.4) were examined with the fluorescence spectrophotometer using a 10-nm emission slit width and an emission wavelength of 530 nm to collect 30 -40 data points (2 s averaging per point) for each labeled lipoprotein fraction, where the g factor was measured prior to each acquisition. Background anisotropies due to scatter were measured using nonlabeled HDL of the same subfraction and subtracted from the data points to yield the final measurement. Means and standard errors were calculated for the anisotropy measurements from each HDL subfraction with SigmaPlot (Systat Software, San Jose, CA). Lipids were extracted from NBD-cholesterol-labeled HDL samples, resolved by TLC, and quantified using a standard char assay, as previously described (8) . Briefly, lipids were extracted twice with 3:2 (vol/vol) hexane-isopropanol, spotted and resolved on Silica gel G TLC plates using 70:30:1 (vol/vol/vol) petroleum ether-diethyl etherglacial acetic acid, and quantified by absorbance at 375 nm after incubation in sulfuric acid at 200°C for 15 min.
Lipoprotein-mediated NBD-cholesterol uptake in cultured primary hepatocytes. Hepatocytes isolated from SCP-2/SCP-x null and WT mice were plated at a density of 1.5 ϫ 10 5 cells per well on collagen-coated two-chamber cover glasses (Nalge Nunc Lab-Tek). After overnight incubation, individual wells were processed for timecourse analysis of NBD-cholesterol uptake. Cells were washed twice with warm (37°C) PBS, incubated for 15 min in PBS at 37°C under 5% CO2, and transferred to a 37°C heated microscope stage for confocal imaging, as described elsewhere (52) . c . Half times and rates were apparent values due to dependence on HDL donor concentrations. Photoshop 7.0 (Adobe Systems, San Jose, CA) and Canvas 7 (ACD Systems, Victoria, BC, Canada) were used to convert select time-course images to tiff format and to compile final multipanel images, respectively.
Western blot analysis of hepatocyte proteins. Western blot analysis was performed on cultured primary hepatocytes isolated from SCP-2/SCP-x null and WT mice to detect levels of proteins (SCP-2, SCP-x, caveolin-1, SRB1, PDZK-1, MAP-17, L-FABP, ABCA1, ABCG1, ABCG5, ABCG8, OSBP, ORP1-7 and ORP9 -11, NPC1, NPC2, NPC1L1, StAR, PC-TP/StARD2, MLN64/StARD3, StARD4, and StARD5), as described elsewhere (5) .
Immunolocalization final wash, the cells were mounted using Invitrogen anti-fade reagents according to the manufacturer's protocol. Primary controls, i.e., wells in which CT-B or anti-SRB1 was not added, and cell samples stained with each probe individually were used to confirm the specificity of each stain. Alternately, cells were rinsed three times in PBS and fixed in a solution of 3.7% formaldehyde with 0.5% glutaraldehyde in PBS for 2 h at 4°C and then blocked and stained with 1:10 -1:50 dilutions of goat anti-SRB1 and rabbit anti-SCP-2 or rabbit anti-SRB1 and goat anti-L-FABP with Alexa Fluor 488-conjugated donkey anti-goat IgG and TRITC-conjugated goat anti-rabbit IgG secondary antibody staining. All incubations and washes were performed in the dark to limit fading. Confocal fluorescence imaging was performed as described above for timecourse studies. Fluorescence emission from labeled cells cultured on coverslips was detected using 488-nm excitation with a HQ530/40 band-pass emission filter for FITC/Alexa Fluor 488-labeled SRB1 (green channel) and 568-nm excitation with a HQ598/40 band-pass emission filter for Alexa Fluor 598-labeled CT-B/TRITC-labeled SCP-2 and L-FABP (red channel). Samples were exposed to the light source for minimal time periods to minimize photobleaching effects. Metamorph 4.0 was used to quantify the fluorescent pixel intensities of individual stains, as well as the peripheral and intracellular localization of those pixels. LaserSharp 3.0 was used to identify the SRB1 pixels colocalized with the cholesterol-rich microdomain/ganglioside M1 (GM1) and SCP signals. SigmaPlot was used to calculate the average integrated intensity of SRB1 (from multiple replicates of each cell type). Excel was used to determine the percentage of total SRB1 signal in peripheral areas of the cells, the percentage of total peripheral SRB1/thresholded area that colocalized with the cholesterol-rich microdomain/GM1 signal, and the percentage of SCP-2 and L-FABP in the cell periphery that colocalized with SRB1. Double-immunogold electron microscopy was performed to determine intermolecular distances between L-FABP and SRB1 similarly, as described elsewhere for SCP-2 and SRB1 (52) .
Isolation of hepatocyte plasma membrane lipid microdomains. Cholesterol-rich and -poor lipid microdomains were isolated from purified plasma membranes derived from cultured primary hepatocytes by affinity chromatography, as described elsewhere (5) . Levels of SRB1, cholesterol, and cholesteryl ester were determined as previously described (5) .
Total hepatic HDL-mediated uptake of NBD-cholesterol in mice. Male 10-to 12-wk-old WT, overexpression, or gene-targeted mice were anesthetized with Avertin (2,2,2-tribromoethanol, 0.25 mg/g body wt ip). After an upper midline incision was made, the gallbladder and the bile duct were exposed. The distal common bile duct was ligated, and the bile duct was cannulated through the fundus of the gallbladder with a polyethylene catheter, which was sutured in position. Collections were performed approximately midway through the light cycle (11 AM-2 PM) on non-food-deprived animals. After an initial collection time, NBD-cholesterol-labeled HDL (0.9 -1.0 mg/ mouse HDL protein) was injected into the hepatic portal vein. Bile was collected for 2 h by gravity while mice were kept under anesthesia at 37°C on a heating pad. At the end of collection time, blood was removed by cardiac puncture, mice were euthanized, and livers were removed. All collected samples were stored at Ϫ20°C until analysis. At 120 min postinjection, blood was collected by cardiac puncture and processed to serum. The mouse was euthanized, and the liver was excised, briefly blotted dry, and weighed. A small piece of liver (0.1 g) was homogenized in 0.5 ml of PBS (pH 7.4)-0.25 M sucrose. A modified Bradford assay was performed on the liver homogenate to determine the protein concentration. Lipids were extracted from the liver homogenate (1 mg protein) and 50 l of serum as well as from 10 l of bile at each time point and analyzed by TLC, as described previously (26) . A standard curve using purified NBD-cholesterol was generated and analyzed by TLC as described above. After TLC, NBD-cholesterol was identified and quantified by an Alpha-Innotech Chemimager system using FluorChem version 2.0 software.
Statistical analysis. Values are means Ϯ SE of the indicated number of replicates (n). Statistical tests between mean values of groups of three or more were performed using one-way ANOVA with Tukey's or Dunnett's post test; statistical variance between groups of two was determined by unpaired t-tests on the selected values using GraphPad Prism (GraphPad Software, San Diego, CA). Differences were statistically significant at P Ͻ 0.05. Fig. 2A) and NBD-cholesterol (Fig. 2B) concentrations of gradient fractions from a representative NBD-cholesterol-labeled HDL preparation indicate the presence of labeled HDL at the highest concentrations in gradient fractions 15 and 16. Excitation spectra of the labeled HDL sample (Fig. 2C) pooled from fractions 15 and 16 exhibit a maximum at 466 nm, indicative of the presence of NBD-cholesterol. The observed emission maximum at 535 nm was consistent with the NBD group located at the alkyl tail of cholesterol being buried in the hydrophobic interior of the HDL, i.e., analogous to cholesterol. Extraction and analysis of lipids showed that NBD-cholesterol was intact (i.e., NBD was attached to the cholesterol) and replaced 15 Ϯ 4% of free sterol without altering total free sterol content. HDL-associated NBD-cholesterol was not esterified, and NBD-cholesterol loading did not alter the composition of other lipids in the HDL (data not shown).
RESULTS
Characterization of NBD-cholesterol-labeled HDL. Protein (
Cultured primary hepatocyte uptake of NBD-cholesterol from HDL. NBD-cholesterol uptake increased over time (Fig. 3A) , localizing within hepatocytes in small punctate structures, as well as diffusely throughout the cytoplasm, but not in nuclei (Fig. 3A) . Uptake was detectable in Ͻ1 min, with a distinct dependence on HDL concentration (Fig. 3B ). HDL at Յ10 g/ml had no effect on half time for maximal uptake ( Fig.  3C ) but increased maximal uptake intensity (Fig. 3D ) and rate of uptake (Fig. 3E ). HDL at Ն20 g/ml results in a short (1-3 min) period of relatively slow uptake and then a rapid increase and conformation to a rise to maximum curve (Fig. 3B) . On the basis of these findings, NBD-cholesterol-labeled HDL concentrations Յ10 g protein/ml were chosen for real-time imaging of uptake in all subsequent studies.
Cultured primary hepatocyte uptake of sterol from other NBD-cholesterol-labeled lipoproteins. Excitation spectra of NBD-cholesterol-labeled LDL (Fig. 4A) and VLDL (Fig. 4B ) exhibited maxima near 466 nm, similar to those of NBDcholesterol in labeled HDL (Fig. 2C) . Similarly, emission maxima at 535 nm indicated that the NBD group located at the alkyl tail of cholesterol was buried in the hydrophobic interior of LDL and VLDL, analogous to cholesterol. However, the order of maximal NBD-cholesterol intensity [VLDL (Fig. 4B) Ͼ LDL (Fig. 4A) ϾϾ HDL (Fig. 2C) ] reflects the total amount of free sterol present (in mg unesterified cholesterol/mg protein: 0.93 in VLDL, 0.29 in LDL, and 0.04 in HDL). Uptake from HDL, LDL, and VLDL was much more rapid than from NBDcholesterol added to buffer alone: VLDL Ͼ LDL Ͼ HDL Ͼ NBD-cholesterol in buffer (Fig. 4C) . However, when normalized for relative lipoprotein cholesterol content, HDL-mediated NBD-cholesterol uptake was significantly increased (HDL Ͼ LDL Ͼ VLDL; Fig. 4D ), similar to the specificity of SRB1-mediated cholesterol uptake from these lipoproteins. Effect of SCP-2/SCP-x gene ablation on sterol uptake from HDL. SCP-2/SCP-x gene ablation significantly increased NBDcholesterol uptake from HDL (Fig. 5A ), especially at low nonsaturating HDL levels (Յ10 g/ml; Fig. 5B ). Uptake was best fit to a single-exponential rise to a maximum in SCP-2/ SCP-x null and WT hepatocytes, indicating that both accessed the same pool of NBD-cholesterol from HDL. At low HDL concentration, SCP-2/SCP-x gene ablation enhanced uptake by shortening the half time of uptake twofold, increasing the maximal uptake rate threefold, and raising the total uptake nearly twofold. SCP-2/SCP-x gene ablation also decreased uptake from LDL (Fig. 5C ) but increased uptake from VLDL (Fig. 5D) .
Specificity for NBD-cholesterol uptake from HDL2 and HDL3. Excitation spectra of NBD-cholesterol in HDL2 (Fig. 6A) and HDL3 (Fig. 6A) were very similar, with excitation maxima at 466 nm, implying that the NBD group located at the alkyl tail of cholesterol was buried in the hydrophobic interior of these lipoproteins. However, maximal intensities were greater for HDL2, indicating that more NBD-cholesterol was incorporated into HDL2. Since total protein in Fig. 6 was held constant (i.e., 10 g/ml), these results were consistent with the known higher free cholesterol content of HDL2 than HDL3 (50) . Finally, anisotropy of NBD-cholesterol within the respective HDL subfractions was similar, indicating similar range of motion for the fluorophore in HDL2 and HDL3.
Effect of SCP-2/SCP-x gene ablation on sterol uptake from HDL2 and HDL3 in cultured primary hepatocytes. NBDcholesterol uptake from HDL2 in hepatocytes from WT mice was faster (shorter half time) and exhibited greater maximum values than that from HDL3 (Fig. 6B, Table 1 ). The higher maximal NBD-cholesterol uptake from HDL2 was likely due to the twofold greater pool size of transferable NBD-cholesterol in HDL2 than HDL3 (Table 1) , consistent with twofold higher loading of NBD-cholesterol into HDL2 than HDL3 achieved during labeling (Fig. 6A) . These data are consistent with the known role of HDL2 as the mature form of HDL that is more effective in cholesterol delivery to hepatocytes.
While SCP-2/SCP-x gene ablation did not affect the maximal rate of NBD-cholesterol uptake from HDL2, the half time of uptake was increased (slowed) slightly (16%, P Ͻ 0.05). This increase was expected to slow NBD-cholesterol uptake from HDL2 but was offset by a slight increase in transferred NBD-cholesterol pool size (Table 1) . Consequently, the curves from HDL2 in SCP-2/SCP-x null and WT hepatocytes were almost superimposable, except at long time periods (Fig. 6C,  inset) . In contrast, uptake from HDL3 was markedly enhanced (Fig. 6D) , with SCP-2/SCP-x gene ablation increasing the maximal rate 1.7-fold and maximal uptake 2-fold and slightly increasing half time of uptake ( Table 1) .
Expression of SRB1 and SRB1 regulatory proteins involved in HDL cholesterol uptake in cultured primary hepatocytes.
To determine if the effects of SCP-2/SCP-2 ablation were due to concomitant upregulation of the HDL receptor (SRB1) or its regulatory proteins, Western blotting was performed. SRB1 was not increased but, instead, decreased 2.4-fold in SCP-2/ SCP-x null hepatocytes (Fig. 7A) . Two accessory proteins (PDZK-1 and MAP-17), thought to influence SRB1 level/ Immunostaining for SRB1 and for the cholesterol-rich microdomain marker GM1 allowed detection of SRB1 at the plasma membrane, as well as intracellularly, in WT (Fig. 7D ) and SCP-2/SCP-x null (Fig. 7G) hepatocytes. SCP-2/SCP-x gene ablation did not alter intracellular localization of SRB1 to the plasma membrane (Table 2 ). GM1 staining was localized primarily at the plasma membrane of WT (Fig. 8E ) and SCP-2/SCP-x null (Fig. 7H) hepatocytes. Superposition of the respective GM1 images with the simultaneously acquired SRB1 images, followed by display of only GM1-colocalized SRB1 pixels, provided a measure of SRB1 distribution in plasma membrane lipid microdomains (Fig. 7, F and I) . SCP-2/SCP-x null hepatocytes exhibited 1.4-fold less SRB1 colocalized within plasma membrane cholesterol-rich microdomains (Table 2) . Also, the relative concentration of SRB1 in cholesterol-rich microdomains affinity-purified from SCP-2/ SCP-x null hepatocytes was decreased 1.8-fold (Table 2) . Thus, although the relative percent distribution of SRB1 to the plasma membrane was not altered by SCP-2/SCP-x gene ablation, SRB1 targeting to plasma membrane cholesterol-rich microdomains was decreased.
Together, these data indicate that the increase in NBDcholesterol uptake from HDL or its subfractions in SCP-2/ SCP-x null hepatocytes was not due to an increased level of SRB1 or an increased distribution of SRB1 to cholesterol-rich plasma membrane microdomains.
Expression of L-FABP, a protein involved in intracellular transport of HDL-derived cholesterol, in cultured primary
hepatocytes from SCP-2/SCP-x null mice. Expression of L-FABP was upregulated nearly twofold in SCP-2/SCP-x null hepatocytes (Fig. 8A) . Since hepatic L-FABP levels are normally at least an order of magnitude higher than SCP-2 levels, L-FABP upregulation in response to SCP-2/SCP-x gene ablation may compensate for the loss of SCP-2 or even increase uptake of HDL-derived free cholesterol.
Additional loss of L-FABP expression (SCP-2/SCP-x/L-FABP null hepatocytes; Fig. 8B ) inhibits the increase observed in the SCP-2/SCP-x null hepatocytes (Fig. 4) . Conversely, overexpression of SCP-2 (Fig. 8C) induces NBDcholesterol uptake from HDL. These data confirm the involvement of L-FABP in compensating for the loss of hepatic SCP-2/SCP-x expression. However, the ability of the SCP-2/SCP-x/L-FABP hepatocytes to continue to take up low levels of HDL-derived sterol suggests the presence/ involvement of other proteins or mechanisms in hepatic flux of unesterified lipoprotein sterol.
Codistribution of L-FABP, as well as SCP-2, with SRB1 in plasma membrane. Confocal microscopy of immunostained hepatocytes showed less than half of cellular SCP-2 and L-FABP at the periphery of cultured hepatocytes (Table 3) . SCP-2 exhibited twofold higher colocalization with SRB1 at the plasma membrane than in the whole cell. In contrast, L-FABP colocalization with SRB1 at the plasma membrane did not differ from that in the whole cell (Table 3) . SCP-2 preferentially (5-fold) distributed into the cholesterol-rich microdomains, while L-FABP was distributed more into cholesterol-poor microdomains (Table 3) . Nevertheless, L-FABP was still ϳ10-fold more prevalent at the plasma membrane in toto, such that a similar amount of L-FABP protein was detected in cholesterol-rich plasma membrane microdomains as SCP-2 protein.
To determine if L-FABP and SRB1 were in close proximity to interact and facilitate uptake of free cholesterol, primary cultured WT hepatocytes were subjected to double-immunogold labeling. Electron microscopy of the double-immunogoldlabeled hepatocytes (Fig. 9A ) detected clusters (inset) of L-FABP and SRB1 at the plasma membrane, with the majority falling at a 10-to 15-nm center-to-center separation distance for 6-nm (L-FABP) and 15-nm (SRB1) gold particles (Fig.   9B ). Since the size of the gold particles (6 and 15 nm) permits closest center-to-center separation of 10.5 nm (i.e., 110 Å), L-FABP and SRB1 were colocalized in sufficiently close proximity to participate in intermolecular interactions similar to observations of SCP-2 and SRB1 at the plasma membrane of WT hepatocytes (52) .
Expression of other proteins involved in intracellular transport of HDL-derived cholesterol (ORPs, StARDs, and NPCs) in cultured primary hepatocytes. Several families of largely organelle-associated (endosome, vesicle, lysosome, mitochondria, and endoplasmic reticulum) proteins also bind and/or facilitate intracellular cholesterol trafficking, primarily in vesicular cholesterol trafficking and targeting molecules to intracellular organelles for oxidation (29, 38, 40, 59) . Western blot analysis showed that SCP-2/SCP-x gene ablation had little to no effect on MLN64 expression (Fig. 10A ) and upregulated StARD4, but not StARD5. While SCP-2/SCP-x gene ablation upregulated PCTP/StARD2 (Fig. 10A) , it enhanced rapid cytoplasmic transfer of phosphatidylcholine, not cholesterol. Thus, with the exception of StARD4, SCP-2/SCP-x gene ablation had little to no effect on the expression of StARD proteins, known to bind/transfer cholesterol. Since StARD4 primarily functions in the mitochondrial delivery of cholesterol for oxidation and there is no evidence suggesting that StARD4 might alter HDL-derived free cholesterol uptake, intracellular transfer to the canaliculus, or biliary cholesterol efflux, upregulation of StARD4 was not expected to affect HDL-mediated NBD-cholesterol uptake.
With regard to the NPC protein family, proteins that participate in the LDL receptor/endosomal/lysosomal pathway for LDL cholesterol uptake, SCP-2/SCP-x gene ablation did not upregulate any NPC protein family members but, instead, selectively decreased NPC1 (Fig. 10B) .
None of the ORP family members have been shown to facilitate cholesterol uptake, and only OSBP and ORP1 bind cholesterol (53, 56) . SCP-2/SCP-x gene ablation did not alter the levels of OSBP (Fig. 10D ) and only slightly (10 -15%) increased the levels of ORP1 (Fig. 10C) . Although ORPs also bind oxysterols and can influence transcriptional and posttranscriptional regulation of cholesterol metabolism via the liver X receptor and sterol regulatory element-binding protein, a sequence search (TFSEARCH, cbrc.jp/research/db/TFSEARCH.html) did not detect a liver X receptor response element in the promoter region of the SCP-2/SCP-x gene. Thus, SCP-2/SCP-x gene ablation elicited little to no change in the expression of the ORP family proteins, such that there was little overall change in the level of ORPs. Values are means Ϯ SE (n ϭ 3-6). Percent colocalization with SRB1 was quantified as percentage of total integrated pixel intensities overlapping with SRB1-specific pixels. Percent signal at the plasma membrane was calculated as percentage of total integrated pixel intensities at the periphery of stained hepatocytes. Percent plasma membrane signal colocalized with SRB1 was calculated as percentage of total integrated peripheral signal per threshold area that colocalized with the SRB1 pixels. L-FABP, liver fatty acid-binding protein. 
Effect of SCP-2 and L-FABP on hepatic HDL-mediated uptake of NBD-cholesterol in vivo.
Liver total uptake of NBD-cholesterol from HDL was significantly increased by overexpression of SCP-2 (Fig. 11A) . Contrary to expectations, SCP-2/SCP-x gene ablation also significantly increased, rather than decreased, liver NBD-cholesterol uptake from HDL (Fig. 11B) , correlating with concomitant upregulation of L-FABP (Fig. 8A) . These effects in vivo were similar to but less dramatic than those in cultured primary hepatocytes (Figs. 8C and 5B), most likely due to a higher effective NBD-cholesterol-labeled HDL in vivo concentration. In contrast, ablation of SCP-2/SCP-x and L-FABP genes decreased liver uptake of NBD-cholesterol from HDL 60% (Fig. 11B) , similar to that observed in the cultured hepatocytes (Fig. 8B) . These results are consistent with HDL-mediated cholesterol uptake being increased (upregulated in SCP-2/SCP-x null) or decreased (absent in SCP-2/SCP-x/L-FABP null).
DISCUSSION
The major source of biliary cholesterol is not hepatic cholesterol synthesized de novo but, instead, free cholesterol derived from lipoproteins, specifically HDL (26, 45) . The general features of RCT include HDL binding to SRB1 at the surface of peripheral tissues/cells, efflux of intracellular cholesterol to the HDL, transport of HDL cholesterol through the vasculature, and binding of HDL to SRB1 at the surface of liver hepatocytes (reviewed in Refs. 14 and 49). HDL binds to SRB1 localized in cholesterol-rich microdo- mains within the hepatocyte basolateral plasma membrane (Fig. 12) (reviewed in Refs. 14 and 49). The majority of HDL free cholesterol then undergoes rapid, nonendocytic uptake, while HDL/cholesteryl esters are taken up by slower endocytic uptake of the HDL particle followed by release of free cholesterol for additional transport within the hepatocyte (reviewed in Refs. 14 and 49). About 5-10% of the HDL free cholesterol rapidly taken up is transported for conversion to bile acids (enzymes in cytoplasm, endoplasmic reticulum, mitochondria, and peroxisomes) and then to the bile canaliculus for cosecretion with HDL-derived free cholesterol into bile for elimination (Fig. 12) (reviewed in Ref. 49) . Although lateral diffusion of cholesterol through the basolateral to the canalicular membrane is also possible (Fig. 12) , lateral diffusion through lipid membranes is much too slow (hours) and further slowed by the tight junction, thus not accounting for the observed rapid transcellular transport of HDL-derived free cholesterol (reviewed in Ref. 49) . We hypothesize that SCP-2 and L-FABP facilitate the intracellular transport of HDL-derived free cholesterol by binding to SRB1 at the basolateral membrane, binding and transporting cholesterol through the cytosol to SRB1 (and/or ABCG5/ABCG8) at the bile canaliculus to facilitate biliary cosecretion of cholesterol with bile acid (Fig. 12) . Since SCP-2 and/or L-FABP also enhance cholesterol transfer to oxidative organelles, stimulate activities of bile acid synthetic enzymes, and bind bile acids, they may also contribute to biliary cholesterol secretion (4, 22, 34) . Finally, SCP-x localized in the peroxisomal matrix is the only known enzyme catalyzing a key step in cholesterol branched side chain oxidation required for bile acid formation (22) . The studies presented here focused on whether SCP-2 and L-FABP facilitated HDL free cholesterol uptake in vivo and in hepatocytes. Since SCP-2 and L-FABP stimulate microsomal acyl-CoA:cholesterol acyltransferase-mediated cholesterol esterification (reviewed in Refs. 22 and 25) , to preclude intracellular esterification as an additional driving force for uptake, NBD-cholesterol was chosen, since hepatocytes do not significantly esterify NBD-cholesterol in the time frame of the uptake experiments presented here (52) . In addition, the orientation of NBD-cholesterol in each lipoprotein was similar to that commonly accepted for free cholesterol, i.e., OH near the surface and alkyl tail buried in the interior of the surface monolayer (50) . NBD-cholesterol loading of the respective lipoproteins was consistent with free cholesterol content of the respective lipoproteins. Furthermore, the preferential uptake of NBD-cholesterol from HDL2 vs. HDL3 and from HDL vs. LDL or VLDL was consistent with SRB1-mediated uptake (17) . The data presented here provide the following new insights.
Real-time uptake of NBD-cholesterol from HDL, HDL2, HDL3, LDL, and VLDL was examined for the first time in cultured primary hepatocytes. The very few studies of HDL cholesterol or cholesterol ester uptake by hepatic cells measured HDL cholesterol ester uptake [cultured primary hepatocytes (32, 43, 44) and hepatoma cells (rat Fu5AH, mouse HepG2, and human Chang liver) (12, 51) ]. While important information has been gained with immortalized human and murine hepatocyte-derived cell lines, they are not a good model for studies of intracellular transport proteins. Cultured hepatoma cell lines express a high level of SRB1 but lack functional ABC transporters (62), lack cholesterol negativefeedback control of cholesterol biosynthesis (31) , and exhibit markedly reduced bile acid, apolipoprotein A1, and apolipoprotein B100 secretion into medium compared with cultured primary hepatocytes (13) . Hepatoma lines have little to no SCP-2 (10, 15, 30, 37, 55) or L-FABP (28, 58) compared with normal liver or hepatocytes. In contrast, expression of SCP-2, L-FABP, ABCG5, and ABCG8 in primary cultured mouse hepatocytes was maintained constant, near normal physiological levels, for up to 4 days in culture, while SRB1, ABCA1, ABCG1, and NPCL1 were relatively constant for 2-3 days in culture.
Uptake kinetics of NBD-cholesterol from HDL, as well as HDL subfractions, were sigmoid in shape, suggesting cooperativity in HDL binding and/or cell/lipoprotein lipid flux. Although sigmoidicity was not observed in studies using liver-derived cell lines (e.g., hepatomas), the time points chosen, over the course of 1-4 h, did not allow resolution of the curves (60, 63) . Nevertheless, the shorter time points (1 min) used in the present work allowed better resolution of early/rapid events and quantification of the initial lipoprotein-hepatocyte flux of sterol. The exact nature of cooperativity remains unknown, but one possibility is that hepatocytes contain high levels of multiple intracellular cholesterol-binding proteins, including not only SCP-2 (0.1% of cytosolic protein) and L-FABP (2-3% of cytosolic protein), but also a variety of other protein families (StARDs, NPCs, and ORPs) involved primarily in vesicular cholesterol trafficking and targeting molecules to intracellular organelles for oxidation (2, 29, 38, 40, 59) . "Patching" of these proteins within SRB1-containing cholesterol-rich plasma membrane microdomains may increase cooperativity to reach a localized threshold level of active receptor and/or receptor-ligand complexes, increasing HDL-mediated NBD-cholesterol uptake over time. Alternately, the sigmoidicity in HDL-mediated NBD-cholesterol uptake by hepatocytes may be indicative of receptor (SRB1 or non-scavenger receptor HDL-binding proteins) and cofactor (e.g., PDZK1 and MAP17) movement from internal sites to the plasma membrane.
SCP-2/SCP-x gene ablation enhanced HDL-mediated NBDcholesterol uptake in these cultured primary hepatocytes. This result was initially surprising in view of the fact that SCP-2 overexpression enhances cholesterol uptake in transfected L cells (39) and increases hepatic cholesterol levels in mice (1, 4, 61) . However, L cells do not express L-FABP (24, 25) , and levels of SCP-2, even when overexpressed, are still much lower than in liver hepatocytes (41) . Interestingly, L-FABP, normally present at 0.2-0.4 mM in hepatic cytosol, was significantly upregulated by SCP-2/SCP-x gene ablation. Although L-FABP binds cholesterol, generally with lower affinity than SCP-2, the total intracellular concentration of L-FABP in hepatocytes (52) and liver (36, 47 ) is Ͼ10-fold higher than that of SCP-2. These findings suggest that upregulation of L-FABP in SCP-2/SCP-x null hepatocytes counteracted the loss of SCP-2. This possibility was supported by the finding that ablation of SCP-2 and L-FABP gene products (i.e., SCP-2/SCP-x/L-FABP null hepatocytes) significantly reduced NBDcholesterol uptake from HDL. In addition, increased sterol uptake from HDL in SCP-2/SCP-x null hepatocytes was not correlated with increased expression of SRB1 (the HDL receptor) in the plasma membrane, redistribution of SRB1 into plasma membrane cholesterol-rich microdomains, or altered expression of several other intracellular cholesterol binding/ trafficking proteins (StARDs, NPCs, and ORPs). Taken together, these data suggest a role for L-FABP and SCP-2 in enhancing HDL free cholesterol uptake in cultured primary hepatocytes.
In vivo studies of NBD-cholesterol uptake in living anesthetized mice largely confirmed measurements in cultured primary hepatocytes. The dramatic decrease of hepatic cholesterol absorption in SCP-2/SCP-x/L-FABP gene-ablated mice, in combination with the slight enhancement in the SCP-2/ SCP-x gene-ablated mice, suggests the involvement of L-FABP, as well as SCP-2, in hepatic HDL free cholesterol uptake.
Finally, the data presented here, together with earlier findings, support the hypothesis that L-FABP and SCP-2 may directly interact with SRB1 and/or ABCG8 to facilitate HDL free cholesterol uptake, intracellular transport, and targeting to bile canaliculus for elimination into bile (Fig. 12) . Double-immunogold electron microscopy showed L-FABP (present study) and SCP-2 (52) in sufficiently close proximity to SRB1 at the basolateral membrane for direct interaction. Similarly, copurification with lipid rafts, double-immunogold electron microscopy, and crosslinking/coimmunoprecipitation detected SCP-2 in close proximity to SRB1 at the canalicular membrane (52) .
In summary, the results presented here show that NBDcholesterol serves as a useful probe for real-time imaging of HDL-mediated cholesterol uptake in cultured primary hepatocytes and in vivo hepatic uptake. SCP-2 and L-FABP contributed significantly to HDL free cholesterol uptake, not only in cultured primary hepatocytes, but also in vivo. However, L-FABP and SCP-2 appeared to differ slightly in HDL substrate specificity. In WT hepatocytes, uptake from HDL2 was severalfold faster and occurred to a greater extent than uptake from HDL3. In contrast, in SCP-2/SCP-x null hepatocytes where L-FABP is upregulated, the uptake of NBD-cholesterol from HDL3 was markedly increased, such that it more closely resembled that from HDL2. The molecular basis for this difference remains to be resolved but would follow from Fig. 12 . Proposed roles of SCP-2 and L-FABP in HDL cholesterol uptake, transport, and excretion into bile. Spontaneous diffusion through cytosol (dotted line), lateral diffusion through membranes, and protein-mediated transport (SCP-2 and L-FABP). Basolateral membranes (white); canalicular membranes (green); cholesterol-rich microdomains (purple); HDL (light orange); ER, endoplasmic reticulum (pink); peroxisomes (yellow); Mito, mitochondria (cyan); SRB1, scavenger receptor B1; ABC transporters G5 and G8; BSEP, ATPdependent bile salt transporter (ABCB11); CYP7A, cholesterol-7␣-hydroxylase; CYP27A, cholesterol-27␣-hydroxylase; SCP-x, sterol carrier protein-X; PM, plasma membrane; C, cholesterol; CE, cholesterol ester; TG, triacylglycerol; PC, phosphatidylcholine; BS, bile salts.
